We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The U.S. Federal Court of Appeals upheld a lower court ruling that bars Actavis’ generic of the osteoarthritis cream Pennsaid (diclofenac) two percent formulation until 2027.